TITLE

Stem cells: Diabetes reversed after transplant

PUB. DATE
January 2015
SOURCE
Nature;1/8/2015, Vol. 517 Issue 7533, p125
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study published in "Cell Stem Cell" which demonstrated how targeting specific immune cells can help prevent the rejection of transplanted stem cell-based pancreatic cells in diabetic mice.
ACCESSION #
100298386

 

Related Articles

  • Haploidentical transplantation in patients with acquired aplastic anemia. Ciceri, F; Lupo-Stanghellini, M T; Korthof, E T // Bone Marrow Transplantation;Feb2013, Vol. 48 Issue 2, p183 

    Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive therapy with antithymocyte globulin and lacking an HLA-matched related or unrelated donor. The platforms of both ex...

  • IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Jol-van der Zijde, C M; Bredius, R G M; Jansen-Hoogendijk, A M; Raaijmakers, S; Egeler, R M; Lankester, A C; van Tol, M J D // Bone Marrow Transplantation;Mar2012, Vol. 47 Issue 3, p360 

    Anti-thymocyte globulin (ATG), raised in rabbits, is frequently used in allogeneic hematopoietic SCT (HSCT), to prevent graft rejection and acute GVHD. In solid organ transplant patients, antibodies to rabbit IgG result in an enhanced clearance of ATG. The occurrence of such antibodies in HSCT...

  • Tell Me More. Mettenburg, Julie // Countdown;Winter2000, Vol. 21 Issue 1, p40 

    Provides answers to readers' questions about diabetes. Barriers in the consideration of stem cell transplantation as a possible cure for diabetes; Research about genes called HLA markers which are associated with risk for diabetes.

  • Salvage allogeneic hematopoietic SCT for primary graft failure in children. Kato, M; Matsumoto, K; Suzuki, R; Yabe, H; Inoue, M; Kigasawa, H; Inagaki, J; Koh, K; Hashii, Y; Tauchi, H; Suminoe, A; Kikuta, A; Sakamaki, H; Kawa, K; Kato, K; Fukuda, T // Bone Marrow Transplantation;Sep2013, Vol. 48 Issue 9, p1173 

    Primary graft failure (pGF) is associated with considerable morbidity and mortality. Salvage hematopoietic SCT (HSCT) can rescue pGF patients; however, the optimal preconditioning regimen and stem cell source are yet to be determined, particularly in children. In this study, we retrospectively...

  • Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Beilhack, Georg F.; Scheffold, Yolanda C.; Weissman, Irving L.; Taylor, Cariel; Jerabek, Libuse; Burge, Matthew J.; Masek, Marilyn A.; Shizuru, Judith A. // Diabetes;Jan2003, Vol. 52 Issue 1, p59 

    Purified hematopoietic stem cells (HSCs) were transplanted into NOD mice to test whether development of hyperglycemia could be prevented. Engraftment of major histocompatibility complex-mismatched HSCs was compared with bone marrow (BM) grafts. HSCs differed from BM because HSCs were more...

  • Human mesenchimal stem cells transplant failed to restore vasodilator potential in vascular tissues from diabetic rats but succeeded in spontaneously hypertensive rats. Soloviev, A. I.; Ivanova, I.; Novokhatska, T.; Klymenko, K. // Proceedings of the Physiological Society;2014, p306P 

    An abstract of the article "Human mesenchimal stem cells transplant failed to restore vasodilator potential in vascular tissues from diabetic rats but succeeded in spontaneously hypertensive rats" by A. I. Soloviev, I. Ivanova, T. Novokhatska and K. Klymenko is presented.

  • FDA approves second liver transplant drug.  // FDA Consumer;Jul/Aug94, Vol. 28 Issue 6, p2 

    Reports that a new drug for preventing organ rejection in liver transplant patients received approval from the Food and Drug Administration (FDA) on April 8, 1994. Information on Prograf (tacrolimus); Immunosuppressant drugs; Adverse effects.

  • Low-Dose ATG Protects against Acute Rejection.  // Kidney;Nov/Dec98, Vol. 7 Issue 6, p267 

    Presents an abstract of the study 'Low-Dose ATG Protects against Acute Rejection,' by D. Thibaudin et al published in 1998.

  • Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin-induced diabetic rat. Qing-Yu Dong; Li Chen; Guan-Qi Gao; Lei Wang; Jun Song; Bo Chen; Yu-Xin Xu; Lei Sun // Clinical & Investigative Medicine;Dec2008, Vol. 31 Issue 6, pE328 

    Background: Bone marrow-derived mesenchymal stem cells (BM-MSCs) are multipotent stroma cells which can provide a potential therapy for diabetes mellitus. But the mechanism is still controversial. Also, the status of BM-MSCs under hyperglycemia is not known. In the present study, we investigated...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics